期刊
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
卷 38, 期 3, 页码 569-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2012.08.012
关键词
Pathophysiology; Inflammatory bowel disease; Ankylosing spondylitis
类别
Inflammatory bowel disease (IBD) is a well-known extra-articular manifestation in spondyloarthritis (SpA); about 6.5% of patients with ankylosing spondylitis develop IBD during the course of the disease. The pathogenesis of both SpA and IBD is considered to be the result of a complex interplay between the host (genetic predisposition), the immune system and environmental factors, notably microorganisms, leading to a disturbed immune system and chronic inflammation. Over the past decade, the role of tumor necrosis factor inhibition (infliximab, etanercept, adalimumab, golimumab) in improving signs and symptoms and overall quality of life has been well documented in various forms of SpA. Future research will clarify the role of other potential targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据